This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Find the latest science, technology and partners in antibody engineering, immunobiology and next generation binders.

REPORT: Antibody Therapeutic Modalities 2020

Share this article

Antibody Therapeutic Modalities Report 2020

Within antibody engineering and therapeutics, there are now a number of different modalities the industry is working on, including monoclonal antibodies (mAbs), protein therapeutics, bispecifics, immuno-oncology checkpoints, antibody-drug conjugates (ADCs) and CAR-T/cellular therapies. At the same time, work on these modalities is increasingly exploring new non-cancer targets.

In May 2020, the Antibody Engineering & Therapeutics conference series conducted a study of industry professionals from around the world. This final report based on 166 survey responses reveals unique insights into the development of and approach to each of these novel modalities.

Explore or download the report by clicking on the image above, or here.


Which of the following types of ​​​​​​therapeutic is your company currently working with?

Antibody therapeutics

Unsurprisingly, mAbs were the most common (79%) type of therapeutic that respondents are working on, followed by 57% of companies developing protein therapeutics and 55% bispecifics.

Over the course of this report, we explore what phase of development companies are in for each modality, what they are targeting, the challenges that still need to be overcome and the enabling technologies and platforms being used.

Key Insights

  • 17% of respondents working on immuno-oncology checkpoints have therapies in Phase III or IV - the highest of any modality.
  • 36% of respondents are working on therapeutics targeting auto-immune diseases - the highest target after cancer.
  • 55% of respondents say that new targets/discovery approaches is the biggest challenge they are facing.
  • 62% of respondents working with mAbs see computational approaches/Machine learning/Artificial Intelligence as the most promising technology for enabling development.

Explore or download the report here.

Share this article

Upcoming event

Antibody Engineering & Therapeutics US

04 - 08 Dec 2022, Delivered as a Hybrid Event
Go to site